American Association for Cancer Research
15357163mct120357-sup-f4_pdf_56k.pdf (56.53 kB)

Supplementary Figure 4 from HER2-Targeted Hybrid Peptide That Blocks HER2 Tyrosine Kinase Disintegrates Cancer Cell Membrane and Inhibits Tumor Growth In Vivo

Download (56.53 kB)
journal contribution
posted on 2023-04-03, 13:42 authored by Megumi Kawamoto, Tomohisa Horibe, Masayuki Kohno, Koji Kawakami

PDF file - 56 KB, Effect of Her2-lytic hybrid peptide on cell viability of H9c2 cells. H9c2 cells were cultured with various concentrations of HER2-lytic hybrid peptide as indicated for 72 h, and cell viability was assessed using WST-8 reagent as described in Materials and Methods section.



HER2 is a transmembrane oncoprotein encoded by the HER2/neu gene and is overexpressed in approximately 20% to 30% of breast cancers. We have recently designed a novel class of drug, the hybrid peptide, which is chemically synthesized and is composed of a target-binding peptide and a lytic peptide containing cationic-rich amino acid components that disintegrate the cell membrane, leading to cancer cell death via membrane lysis. In this study, we designed a HER2-binding peptide linked to this novel lytic peptide, which we termed the HER2-lytic hybrid peptide and assessed the cytotoxic activity of this hybrid peptide in vitro and in vivo. The HER2-lytic hybrid peptide showed high cytotoxic activity against all ovarian and breast cancer cell lines, even trastuzumab- and/or lapatinib-resistant cells, but not against normal cells. Competition assays using anti-HER2 antibody and knockdown of this receptor by siRNA confirmed the specificity of the HER2-lytic hybrid peptide. In addition, it was shown that the HER2-lytic hybrid peptide can disintegrate the cancer cell membrane of HER2-overexpressing SK-BR-3 cancer cells in only 5 minutes, but not normal cells, and block HER2 signaling. Intravenous administration of the HER2-lytic peptide in the athymic mouse implanted with BT-474 and MDA-MB-453 cells significantly inhibited tumor progression. The HER2-lytic hybrid peptide was effective even in breast cancer cell lines that are resistant to trastuzumab and/or lapatinib in vitro and in vivo. Therefore, this hybrid peptide may provide a potent treatment option for patients with cancer. Mol Cancer Ther; 12(4); 384–93. ©2013 AACR.

Usage metrics

    Molecular Cancer Therapeutics



    Ref. manager